Dr. Lisa Dwane post doc with Prof. Darran O’Connor’s group, is Irish Cancer Society’s PhD Scholar of the Year 2019. She presenting her research in layman’s terms to compete for the prize at the ICS Research Awards held on Friday 15th February, at the House of Lords, Bank of Ireland College Green, Dublin 2.
Lisa also received the EACR Young Scientist Award, in the Junior category, for her research in cancer research. This Young Scientist award is granted to the two applicants with the highest scoring abstracts. This year, both recipients are RCSI researchers; the second applicant Dr. Sara Charmsaz, Dept. of Surgery, received the Senior award. Awards will be presented at the IACR Annual Conference, on Friday 22nd February, in Belfast.
Lauren Fagan (co-supervised by Dr. Oran Kennedy and Dr. Annie Curtis) was awarded Best Musculoskeletal Research Oral Presentation – Early Researcher Category for her early stage work on the chondrocyte clock and post-traumatic osteoarthritis at the Royal Academy of Medicine in Ireland Section of Bioengineering 25th Annual Conference (BinI 2019), UL, 18th – 19thJanuary 2019.
On Thursday 4 October, the Equality, Diversity and Inclusion (EDI) unit welcomed almost 30 family members of staff to RCSI St Stephen’s Green campus for the first-ever RCSI Intergenerational Day. Throughout the day, the guests had the opportunity to learn about a variety of activities at RCSI. MCT hosted a lab tour where guests were introduced to several MCT Principal Investigators who discussed their work and demonstrated how their research is carried out. Four stations focusing on the themes of Breast Cancer, Novel Cancer Therapies, Multiple Sclerosis and Circadian Rhythm and its Impact on Health were featured, led by Dr Sudipto Das, Dr Maria Morgan, Prof Tracy Robson, Dr Claire McCoy and Dr Annie Curtis. Guests were guided around the labs by the MCT Operations Team John O’Brien, Olwen Foley, Anne Grady, Mary Ledwith and Seamus McDonald. Scientists Stephanie Annett; Gillian Moore;Conor Duffy; Chiara DeSanti; Mariana Cervantes Silva, Richard Carroll and George Timmons also volunteered on the day.
Prof Gianpiero Cavalleri contributed to the day’s activities with a talk on the Irish DNA Atlas. The MCT research projects presented were a hit with our audience evident by the number of attendees, their level of engagement and thoughtful questions. Guests included relatives of MCT staff including Mr Joseph Tighe father of Orna and Mrs McDonald & Curtis – mothers of Seamus and Annie respectively. Julia Morrow of the EDI unit commented that ‘between the MCT lab visit and Gianpiero’s talk, more than one guest commented they wish they could go back and have a more science-oriented career!’ It’s never too late we say!
Please join me in offering congratulations to ‘Drs’ Shane O’Grady and Brian Mooney who successfully defended their PhD thesis yesterday:
Shane’s: Investigation of the functional roles of calcium channels, inflammatory cytokines and tumour micro-environmental factors in a human in vitro model of breast cancer calcification
Supervisor: Maria Morgan
Brian’s: The role of the anorectic neuropeptide CART in breast cancer. Supervisor: Darran O’Connor
Irish Association for Cancer Research – Annual Meeting takes place at Newpark Hotel, Kilkenny on Thursday 23 and Friday 24 February 2017.
MCT cancer researchers secured oral presentations at different sessions. Prof Ray Stallings is a guest speaker at the Plenary Session focused on challenges in childhood cancers. He will be discussing ‘Modulation of neuroblastoma phenotype with epigenetically regulated miRNAs’.
Stephanie Annett will be giving a talk ‘FKBPL as a novel prognostic biomarker and therapeutic agent in high-grade serous ovarian cancer’ at Proffered Paper Session on Thursday morning. Two Irish Cancer Society funded PhD students will be discussing their findings at the Irish Cancer Society Scholar and Fellow Presentation session. Louise Walsh – ‘RNA sequencing identifies bromodomain proteins as a therapeutic strategy for invasive lobular carcinoma’ and Brian Mooney – ‘Expression of the cocaine- and amphetamine-regulated transcript recruits BAF chromatin remodelling complexes to the estrogen receptor’.
Survival rates for breast cancer have risen significantly over the past few decades, in large part due to a considerable increase in the number of tumours detected via mammography at an early, more easily-treated stage. The presence of microcalcifications on a mammogram constitutes an important diagnostic clue to radiographers, with approximately 30% of invasive breast tumours and up to 90% of cases of ductal carcinoma in situ (DCIS) being detected by the presence of calcifications. Some studies have also suggested that the presence of calcifications may act as a prognostic factor, as patients presenting with breast tumours with associated calcifications have a worse prognosis than those without.
Despite their importance in breast cancer diagnosis, the exact mechanism by which microcalcifications are formed remains largely unexplored. Our group previously established the first in vitro model of mammary cell microcalcification (1) which we have recently extended to the human the breast cancer cell line MDA-MB-231. When cultured with a cocktail of osteogenic-reagents for a prolonged period, these cells produce deposits of calcium phosphate.
Using a combination of histological staining, quantitative measurement of calcium content, alkaline phosphatase activity and analysis of gene expression, we can monitor the changes in cell phenotype leading to onset of mineralisation. The nature of our model allows for easy manipulation of cell culturing conditions and by adding various inhibitory compounds or cytokines to our culture media, we can identify the key pathways and targets necessary for calcification production. In doing so, we hope to build up a comprehensive understanding of the cellular and molecular basis underlying the formation of these important diagnostic clues.
Breast cancer currently affects 1 in 8 women in Ireland, with over 3000 reported cases each year. The most common subtype of breast cancer, known as Estrogen Receptor positive (ER+) breast cancer, accounts for roughly 70% of all breast cancers diagnosed. The most common drug used to treat this disease (Tamoxifen) works by preventing estrogen from driving the growth of the cancer cells, however, roughly 1 in 3 women will be resistant to tamoxifen treatment, highlighting the need for further research into this field. A number of years ago, though mining of publically available datasets, we identified a gene known as CART to be a marker of poor prognosis in ER+ breast cancer. CART (The Cocaine- and Amphetamine-Regulated Transcript) is a neuropeptide involved in processes such as feeding and drug reward. We have identified that high expression of CART in breast cancer patients correlates with poor overall survival, and also a poor response to tamoxifen. We also demonstrated that CART could influence the activity of ERα in a ligand-independent manner . Our current research focuses on combining proteomic (mass-spectrometry) and transcriptomic (RNA-seq) approaches in order to fully understand the role CART plays in ER+ breast cancer. We aim to modulate the expression of these identified targets in order to investigate whether any of these targets could slow the growth of breast cancer cells in vitro. Combining these approaches, we hope to identify novel therapeutic opportunities for patients with ER+ breast cancer.
Following completion of my Pharmacology degree in UCD, I began a PhD in breast cancer research under the supervision of Dr. Darran O’Connor, a career I have always been very determined to follow. My research is focused on endocrine-driven breast cancer and understanding the molecular mechanisms that drive this subtype of cancer. Currently, half of breast cancer patients that receive anti-endocrine therapies will relapse, so there is an urgent need for the identification of novel therapeutic targets. Our research is focused on the deubiquitinating enzyme USP11, which we believe plays a key role in driving endocrine-driven breast cancer. When we silence USP11 in vitro, we see a reduction in estrogen receptor activity and cell viability. During the final year of my PhD, I hope to elucidate the mechanism by which USP11 plays this role, and determine the prognostic relevance of USP11 in breast cancer. This could potentially lead to a better understanding of endocrine-driven breast cancer and with further validation, USP11 may represent a novel therapeutic target.
As a pharmacologist, I was thrilled to win best oral presentation at the Irish Association of Pharmacologists Annual Meeting! The standard of talks throughout the day were excellent, with a wide range of topics explored. I was also a finalist for the Irish Cancer Society’s Researcher of the Year Award, which took place 1st December at Trinity College Dublin. The purpose of the evening was to communicate our research to a lay audience, which proved more difficult than expected! Although I didn’t take home the award it was a very enjoyable evening, and the experience was invaluable. As scientists it is important for us to share and communicate our research with the general public and this was a skill I gained from the night!